世界のエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）市場予測（～2028年）：60 KIU、50 KIU

• 英文タイトル：Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

• レポートコード：GIR-22E8805 • 出版社/出版日：GlobalInfoResearch / 2022年5月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 GlobalInfoResearchの最新の調査によると、世界のエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメントは次をカバーします。 ・60 KIU、50 KIU 用途別セグメントは次のように区分されます。 ・出血、手術支援、血小板無力症、血友病B、血友病A、頭部外傷、その他 世界のエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）市場の主要な市場プレーヤーは以下のとおりです。 ・BMS、Generium、Novo Nordisk、Shire (Baxter)、Bayer、CSL、Pfizer、Grifols、Biogen、Octapharma、NovoNordisk、Greencross、Kedrion、BPL、Hualan Bio、RAAS、Suzhou Alphamab 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）メーカーの企業概要、2019年～2022年までのエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2017年～2028年までの地域別エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の販売量、売上、成長性を示しています。 ・第5、6章では、2017年～2028年までのエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）市場予測を収録しています。 ・第12章では、主要な原材料、主要なサプライヤー、およびエプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の産業チェーンを掲載しています。 ・第13、14、15章では、エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。 ***** 目次(一部) ***** ・市場概要 ・メーカー情報（企業概要、製品概要、販売量、価格、売上）：BMS、Generium、Novo Nordisk、Shire (Baxter)、Bayer、CSL、Pfizer、Grifols、Biogen、Octapharma、NovoNordisk、Greencross、Kedrion、BPL、Hualan Bio、RAAS、Suzhou Alphamab ・メーカー別市場シェア ・地域別市場分析2017年-2028年 ・種類別分析2017年-2028年：60 KIU、50 KIU ・用途別分析2017年-2028年：出血、手術支援、血小板無力症、血友病B、血友病A、頭部外傷、その他 ・エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ ・エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア ・エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア ・エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の南米市場規模2017年-2028年：ブラジル、アルゼンチン ・エプタコグアルファ（遺伝子組換え活性型血液凝固第VII因子）の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Bleeding accounting for % of the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While 60 KIU segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) include BMS, Generium, Novo Nordisk, Shire (Baxter), and Bayer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
60 KIU
50 KIU
Market segment by Application can be divided into
Bleeding
Surgery Assisted
Glanzmann Plateletasthenia
Hemophilia B
Hemophilia A
Head Trauma
Others
The key market players for global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market are listed below:
BMS
Generium
Novo Nordisk
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Suzhou Alphamab
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), with price, sales, revenue and global market share of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) from 2019 to 2022.
Chapter 3, the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa).
Chapter 13, 14, and 15, to describe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 60 KIU
1.2.3 50 KIU
1.3 Market Analysis by Application
1.3.1 Overview: Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Bleeding
1.3.3 Surgery Assisted
1.3.4 Glanzmann Plateletasthenia
1.3.5 Hemophilia B
1.3.6 Hemophilia A
1.3.7 Head Trauma
1.3.8 Others
1.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size & Forecast
1.4.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume (2017-2028)
1.4.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (2017-2028)
1.5 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity Analysis
1.5.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Total Production Capacity (2017-2028)
1.5.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Drivers
1.6.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Restraints
1.6.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Trends Analysis
2 Manufacturers Profiles
2.1 BMS
2.1.1 BMS Details
2.1.2 BMS Major Business
2.1.3 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.1.4 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Generium
2.2.1 Generium Details
2.2.2 Generium Major Business
2.2.3 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.2.4 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novo Nordisk
2.3.1 Novo Nordisk Details
2.3.2 Novo Nordisk Major Business
2.3.3 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.3.4 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Shire (Baxter)
2.4.1 Shire (Baxter) Details
2.4.2 Shire (Baxter) Major Business
2.4.3 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.4.4 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Bayer
2.5.1 Bayer Details
2.5.2 Bayer Major Business
2.5.3 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.5.4 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 CSL
2.6.1 CSL Details
2.6.2 CSL Major Business
2.6.3 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.6.4 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.7.4 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 Grifols
2.8.1 Grifols Details
2.8.2 Grifols Major Business
2.8.3 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.8.4 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Biogen
2.9.1 Biogen Details
2.9.2 Biogen Major Business
2.9.3 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.9.4 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Octapharma
2.10.1 Octapharma Details
2.10.2 Octapharma Major Business
2.10.3 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.10.4 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 NovoNordisk
2.11.1 NovoNordisk Details
2.11.2 NovoNordisk Major Business
2.11.3 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.11.4 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Greencross
2.12.1 Greencross Details
2.12.2 Greencross Major Business
2.12.3 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.12.4 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13 Kedrion
2.13.1 Kedrion Details
2.13.2 Kedrion Major Business
2.13.3 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.13.4 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14 BPL
2.14.1 BPL Details
2.14.2 BPL Major Business
2.14.3 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.14.4 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15 Hualan Bio
2.15.1 Hualan Bio Details
2.15.2 Hualan Bio Major Business
2.15.3 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.15.4 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16 RAAS
2.16.1 RAAS Details
2.16.2 RAAS Major Business
2.16.3 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.16.4 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17 Suzhou Alphamab
2.17.1 Suzhou Alphamab Details
2.17.2 Suzhou Alphamab Major Business
2.17.3 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product and Services
2.17.4 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Breakdown Data by Manufacturer
3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
3.4 Market Concentration Rate
3.4.1 Top 3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturer Market Share in 2021
3.4.2 Top 6 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Manufacturer Market Share in 2021
3.5 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Region
4.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Region (2017-2028)
4.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2017-2028)
4.2 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (2017-2028)
4.3 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (2017-2028)
4.4 Asia-Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (2017-2028)
4.5 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (2017-2028)
4.6 Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Type (2017-2028)
5.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type (2017-2028)
5.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Application (2017-2028)
6.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application (2017-2028)
6.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2028)
7.2 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2028)
7.3 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country
7.3.1 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Country (2017-2028)
7.3.2 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2028)
8.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2028)
8.3 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country
8.3.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Country (2017-2028)
8.3.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2028)
9.2 Asia-Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2028)
9.3 Asia-Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Region
9.3.1 Asia-Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2028)
10.2 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2028)
10.3 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country
10.3.1 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Country (2017-2028)
10.3.2 South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2017-2028)
11.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2017-2028)
11.3 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country
11.3.1 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) and Key Manufacturers
12.2 Manufacturing Costs Percentage of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
12.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Process
12.4 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Typical Distributors
13.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

---